Skip to main content
Clinical Trials/CTRI/2022/11/047205
CTRI/2022/11/047205
Not yet recruiting
未知

To develop NEAR AI, a model to predict response to immune checkpoint inhibitor therapy in Non Small Cell Lung carcinoma (NSCLC).

Kerala Startup Mission0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Sponsor
Kerala Startup Mission
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Sponsor
Kerala Startup Mission

Eligibility Criteria

Inclusion Criteria

  • 1\. Non small cell carcinoma lung of any histology who have received treatment with immune checkpoint inhibitor therapy between 2017\-2021\.
  • 2\. Patients should have taken regular treatment as per prescribed protocol for at least 3 months or till first radiological response assessment by iRESIST, whichever is later.
  • 3\. Drug treatments include Pembrolizumab/Nivolumab/Durvalumab/Atezolizumab either in combination with chemotherapy or as single agents.
  • 4\. Stage IV or recurrent disease.
  • 5\. Any line of treatment is included
  • 6\. Combination with radiation is included
  • 7\. Hematoxylin â?? Eosin slide with/without corresponding FFPE block of tumor biopsy tissue is available.
  • 8\. Clinical record of response to ICI therapy is available.

Exclusion Criteria

  • 1\. Documented infectious pneumonia during first 3 months of therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials